| (210) | Number of the EPO application | 17808224 |
| (220) | Filing date of the EPO application | 2017.11.01 |
| (80) | EPO patent specification publication (B) | EPB nr. 36/2021, 2021.09.08 |
| (110) | EPO patent number | 3535298 |
| (11) | Number of the document | MD 3535298 T2 |
| (21) | Number of the application | e 2019 1012 |
| (71) | Name(s) of applicant(s), code of the country | Jounce Therapeutics, Inc., US; |
| (72) | Name(s) of inventor(s), code of the country | MABRY George Robert III, US;
SAZINSKY Stephen, US; |
| (73) | Name(s) of owner(s), code of the country | JOUNCE Therapeutics Inc., US; |
| (54) | Title of the invention | Antibodies to PD-1 and uses thereof |
| (13) | Kind-of-document code | T2 |
| (51) | International Patent Classification | C07K 16/28 (2006.01.01); A61P 35/00 (2006.01.01) |
| (19) | Country | US |
| (41) | Date of publication of the application | 2019.10.31 |
| (49) | Date of publication of the translation of the validated European patent specification | 2022.01.31 |
| (30) | Priority | 201662416602 P, 2016.11.02, US |
| (74) | Patent attorney | (Procedură) FOCŞA Valentin, bd. Renaşterii Naţionale, No. 6, of. 08, MD-2024, mun. Chişinău, Republica Moldova |
| (86) | International application | PCT/US2017/059481, 2017.11.01 |
| (87) | International publication | WO 2018/085358, 2018.05.11 |